Skba Capital Management LLC Has $12.84 Million Holdings in Kenvue Inc. (NYSE:KVUE)

Skba Capital Management LLC boosted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 601,330 shares of the company's stock after purchasing an additional 36,070 shares during the period. Kenvue makes up about 2.0% of Skba Capital Management LLC's investment portfolio, making the stock its 14th biggest holding. Skba Capital Management LLC's holdings in Kenvue were worth $12,838,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of KVUE. Handelsbanken Fonder AB raised its stake in shares of Kenvue by 2.9% during the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after purchasing an additional 21,222 shares during the period. Alberta Investment Management Corp lifted its holdings in Kenvue by 23.2% in the 4th quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after buying an additional 109,700 shares in the last quarter. Longbow Finance SA grew its stake in shares of Kenvue by 5.0% during the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after acquiring an additional 13,287 shares in the last quarter. Steward Partners Investment Advisory LLC increased its position in shares of Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock worth $1,023,000 after acquiring an additional 28,216 shares during the last quarter. Finally, CORDA Investment Management LLC. boosted its holdings in Kenvue by 1.4% in the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock valued at $26,754,000 after purchasing an additional 17,466 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Kenvue Stock Performance

NYSE KVUE traded down $0.18 during trading hours on Thursday, hitting $23.69. The company had a trading volume of 15,703,942 shares, compared to its average volume of 16,740,461. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm has a market cap of $45.28 billion, a P/E ratio of 44.62, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $22.50 and a 200-day simple moving average of $22.47.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a yield of 3.46%. The ex-dividend date was Wednesday, February 12th. Kenvue's dividend payout ratio is presently 154.72%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 target price on the stock. UBS Group reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a research note on Friday, February 7th. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a research report on Monday, February 24th. Citigroup cut their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Finally, Deutsche Bank Aktiengesellschaft downgraded Kenvue from a "buy" rating to a "hold" rating and decreased their price target for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $24.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.